Dexrazoxane Exposure and Risk of Secondary Acute Myeloid Leukemia in Pediatric Oncology Patients

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2014 Mar 27

PMID 24668949

Citations 38

Authors

Alix E Seif

Dana M Walker

Yimei Li

Yuan-Shung V Huang

Marko Kavcic

Kari Torp

Rochelle Bagatell

Brian T Fisher

Richard Aplenc

Affiliations

Soon will be listed here.

Abstract

Background: Dexrazoxane may reduce anthracycline-associated cardiotoxicity in pediatric cancer patients. However, concerns of secondary acute myeloid leukemia (AML) have led to restrictions on pediatric dexrazoxane use in Europe. Published data about dexrazoxane-associated secondary AML are limited and conflicting. We sought to estimate the secondary AML risk in children receiving dexrazoxane after anthracycline exposure.

Procedure: A retrospective cohort of children with newly identified malignancies (excluding AML) receiving anthracyclines between January 1, 1999 and March 31, 2011 was established using the Pediatric Health Information System (PHIS). Patients were followed for all subsequent admissions to identify dexrazoxane exposures and secondary AML, defined by AML ICD-9 codes and AML induction chemotherapy. Logistic regression was used to model the association of dexrazoxane and secondary AML risk. A propensity score was used to adjust for measurable confounding.

Results: Of 15,532 patients in the cohort exposed to anthracyclines, 1,406 received dexrazoxane. The secondary AML rate was 0.21% (3 of 1,046) in dexrazoxane-exposed and 0.55% (77 of 14,126) in unexposed patients. In a propensity score-adjusted multivariate analysis, dexrazoxane exposure was not associated with an increased risk of secondary AML, OR = 0.38, 95% CI 0.11-1.26.

Conclusions: Dexrazoxane was not associated with an increased risk of secondary AML in a large cohort of pediatric cancer patients receiving anthracyclines in US hospitals. While these data support dexrazoxane's safety in the general pediatric oncology population, additional studies are needed to confirm these findings and to quantify dexrazoxane's long-term cardioprotective effects.

Citing Articles

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

Liu D, Liu J, Xiao R, Deng A, Liu W Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770581 PMC: 11678267. DOI: 10.3390/ph17121739.

Molecular Mechanisms and Therapeutic Targeting of Ferroptosis in Doxorubicin-Induced Cardiotoxicity.

Wu L, Zhang Y, Wang G, Ren J JACC Basic Transl Sci. 2024; 9(6):811-826.

PMID: 39070280 PMC: 11282888. DOI: 10.1016/j.jacbts.2023.10.009.

Metformin Inhibits Autophagy, Mitophagy and Antagonizes Doxorubicin-Induced Cardiomyocyte Death.

Van J, Hahn Y, Silverstein B, Li C, Cai F, Wei J Int J Drug Discov Pharm. 2024; 2(1):37-51.

PMID: 38487671 PMC: 10939033. DOI: 10.53941/ijddp.0201004.

Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database.

Cao L, Huang Y, Wu C, Getz K, Miller T, Ruiz J Pediatr Blood Cancer. 2023; 70(5):e30260.

PMID: 36815580 PMC: 10402395. DOI: 10.1002/pbc.30260.

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.

Chow E, Aggarwal S, Doody D, Aplenc R, Armenian S, Baker K J Clin Oncol. 2023; 41(12):2248-2257.

PMID: 36669148 PMC: 10448941. DOI: 10.1200/JCO.22.02423.

References

Hudson M, Ness K, Gurney J, Mulrooney D, Chemaitilly W, Krull K . Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309(22):2371-2381. PMC: 3771083. DOI: 10.1001/jama.2013.6296. View

Rubin D . Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1998; 127(8 Pt 2):757-63. DOI: 10.7326/0003-4819-127-8_part_2-199710151-00064. View

Kim M, Goldberg J . The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med. 2001; 20(14):2065-78. DOI: 10.1002/sim.847. View

Wexler L, Andrich M, Venzon D, Berg S, Chen C, Dilsizian V . Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996; 14(2):362-72. DOI: 10.1200/JCO.1996.14.2.362. View

van Dalen E, van der Pal H, Kok W, Caron H, Kremer L . Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006; 42(18):3191-8. DOI: 10.1016/j.ejca.2006.08.005. View

Salzer W, Devidas M, Carroll W, Winick N, Pullen J, Hunger S . Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2009; 24(2):355-70. PMC: 4300959. DOI: 10.1038/leu.2009.261. View

Barry E, Vrooman L, Dahlberg S, Neuberg D, Asselin B, Athale U . Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008; 26(7):1106-11. DOI: 10.1200/JCO.2007.12.2481. View

Walker D, Fisher B, Seif A, Huang Y, Torp K, Li Y . Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer. 2012; 60(4):616-20. PMC: 3918414. DOI: 10.1002/pbc.24270. View

Vrooman L, Neuberg D, Stevenson K, Asselin B, Athale U, Clavell L . The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011; 47(9):1373-9. PMC: 3736806. DOI: 10.1016/j.ejca.2011.03.022. View

10.

Steinherz L, Steinherz P, Tan C, Heller G, Murphy M . Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266(12):1672-7. View

11.

Silber J, Jakacki R, Larsen R, Goldwein J, Barber G . Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993; 21(7):477-9. DOI: 10.1002/mpo.2950210704. View

12.

Schiavetti A, Castello M, Versacci P, Varrasso G, Padula A, Ventriglia F . Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol. 1997; 14(3):213-22. DOI: 10.3109/08880019709009491. View

13.

Tebbi C, Mendenhall N, London W, Williams J, Hutchison R, Fitzgerald T . Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012; 59(7):1259-65. PMC: 3468662. DOI: 10.1002/pbc.24279. View

14.

Speyer J, Green M, Kramer E, Rey M, Sanger J, Ward C . Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988; 319(12):745-52. DOI: 10.1056/NEJM198809223191203. View

15.

Hasinoff B . The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions. 1989; 26(3-4):378-85. DOI: 10.1007/BF01967305. View

16.

Feudtner C, Hays R, Haynes G, Geyer J, Neff J, Koepsell T . Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics. 2001; 107(6):E99. DOI: 10.1542/peds.107.6.e99. View

17.

Kavcic M, Fisher B, Torp K, Li Y, Huang Y, Seif A . Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatr Blood Cancer. 2012; 60(3):508-11. PMC: 3684426. DOI: 10.1002/pbc.24402. View

18.

Lipshultz S, Scully R, Lipsitz S, Sallan S, Silverman L, Miller T . Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010; 11(10):950-61. PMC: 3756093. DOI: 10.1016/S1470-2045(10)70204-7. View

19.

Ginsberg J, Cnaan A, Zhao H, Clark B, Paridon S, Chin A . Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines. J Clin Oncol. 2004; 22(15):3149-55. DOI: 10.1200/JCO.2004.01.047. View

20.

Landier W, Bhatia S, Eshelman D, Forte K, Sweeney T, Hester A . Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004; 22(24):4979-90. DOI: 10.1200/JCO.2004.11.032. View